

PDGFRA-associated chronic eosinophilic leukemia

Description

PDGFRA-associated chronic eosinophilic leukemia is a form of blood cell cancer characterized by an elevated number of cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in *PDGFRA*-associated chronic eosinophilic leukemia.

Another characteristic feature of *PDGFRA*-associated chronic eosinophilic leukemia is organ damage caused by the excess eosinophils. Eosinophils release substances to aid in the immune response, but the release of excessive amounts of these substances causes damage to one or more organs, most commonly the heart, skin, lungs, or nervous system. Eosinophil-associated organ damage can lead to a heart condition known as eosinophilic endomyocardial disease, skin rashes, coughing, difficulty breathing, swelling (edema) in the lower limbs, confusion, changes in behavior, or impaired movement or sensations. People with *PDGFRA*-associated chronic eosinophilic leukemia can also have an enlarged spleen (splenomegaly) and elevated levels of certain chemicals called vitamin B12 and tryptase in the blood.

Some people with *PDGFRA*-associated chronic eosinophilic leukemia have an increased number of other types of white blood cells, such as neutrophils or mast cells. Occasionally, people with *PDGFRA*-associated chronic eosinophilic leukemia develop other blood cell cancers, such as acute myeloid leukemia or B-cell or T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

PDGFRA-associated chronic eosinophilic leukemia is often grouped with a related condition called hypereosinophilic syndrome. These two conditions have very similar signs and symptoms; however, the cause of hypereosinophilic syndrome is unknown.

Frequency

PDGFRA-associated chronic eosinophilic leukemia is a rare condition; however, the exact prevalence is unknown.

Causes

PDGFRA-associated chronic eosinophilic leukemia is caused by mutations in the *PDGFRA* gene. This condition usually occurs as a result of genetic rearrangements that

fuse part of the *PDGFRA* gene with part of another gene. Rarely, changes in single DNA building blocks (point mutations) in the *PDGFRA* gene are found in people with this condition. Genetic rearrangements and point mutations affecting the *PDGFRA* gene are somatic mutations, which are mutations acquired during a person's lifetime that are present only in certain cells. The somatic mutation occurs initially in a single cell, which continues to grow and divide, producing a group of cells with the same mutation (a clonal population).

The most common genetic abnormality in *PDGFRA*-associated chronic eosinophilic leukemia results from a deletion of genetic material from chromosome 4, which brings together part of the *PDGFRA* gene and part of the *FIP1L1* gene, creating the *FIP1L1-PDGFRA* fusion gene.

The *FIP1L1* gene provides instructions for a protein that plays a role in forming the genetic blueprints for making proteins (messenger RNA or mRNA).

The *PDGFRA* gene provides instructions for making a receptor protein that is found in the cell membrane of certain cell types. Receptor proteins have specific sites into which certain other proteins, called ligands, fit like keys into locks. When the ligand attaches (binds), the *PDGFRA* receptor protein is turned on (activated), which leads to activation of a series of proteins in multiple signaling pathways. These signaling pathways control many important cellular processes, such as cell growth and division (proliferation) and cell survival.

The *FIP1L1-PDGFRA* fusion gene (as well as other *PDGFRA* fusion genes) provides instructions for making a fusion protein that has the function of the normal *PDGFRA* protein. However, the fusion protein does not require ligand binding to be activated. Similarly, point mutations in the *PDGFRA* gene can result in a *PDGFRA* protein that is activated without ligand binding. As a result, the signaling pathways are constantly turned on (constitutively activated), which increases the proliferation and survival of cells. When the *FIP1L1-PDGFRA* fusion gene mutation or point mutations in the *PDGFRA* gene occur in blood cell precursors, the growth of eosinophils (and occasionally other blood cells, such as neutrophils and mast cells) is poorly controlled, leading to *PDGFRA*-associated chronic eosinophilic leukemia. It is unclear why eosinophils are preferentially affected by this genetic change.

[Learn more about the genes and chromosome associated with *PDGFRA*-associated chronic eosinophilic leukemia](#)

- *FIP1L1*
- *PDGFRA*
- chromosome 4

Inheritance

PDGFRA-associated chronic eosinophilic leukemia is not inherited and occurs in people with no history of the condition in their families. Mutations that lead to a *PDGFRA* fusion

gene and *PDGFRA* point mutations are somatic mutations, which means they occur during a person's lifetime and are found only in certain cells. Somatic mutations are not inherited. Males are more likely to develop *PDGFRA*-associated chronic eosinophilic leukemia than females because, for unknown reasons, *PDGFRA* fusion genes are found more often in males.

Other Names for This Condition

- Chronic eosinophilic leukemia with FIP1L1-PDGFRA
- Myeloid and lymphoid neoplasms associated with PDGFRA rearrangement
- Myeloid and lymphoid neoplasms with PDGFRA rearrangement
- Myeloid/lymphoid neoplasms with PDGFRA rearrangement
- PDGFRA-associated myeloproliferative neoplasm

Additional Information & Resources

Genetic Testing Information

- Genetic Testing Registry: Idiopathic hypereosinophilic syndrome (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0206141/>)

Genetic and Rare Diseases Information Center

- Hypereosinophilic syndrome (<https://rarediseases.info.nih.gov/diseases/2804/index>)

Patient Support and Advocacy Resources

- National Organization for Rare Disorders (NORD) (<https://rarediseases.org/>)

Catalog of Genes and Diseases from OMIM

- HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES (<https://omim.org/entry/607685>)

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28chronic+eosinophilic+leukemia%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1440+days%22%5Bdp%5D>)

References

- Buitenhuis M, Verhagen LP, Cools J, Coffey PJ. Molecular mechanisms underlying FIP1L1-PDGFR α -mediated myeloproliferation. *Cancer Res.* 2007 Apr 15; 67(8):3759-66. doi: 10.1158/0008-5472.CAN-06-4183. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17440089>)
- Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFR α and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med.* 2003 Mar 27;348(13):1201-14. doi: 10.1056/NEJMoa025217. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/12660384>)
- Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hofmann WK, Berdel WE, Muller-Tidow C, Reiter A, Koschmieder S. Novel imatinib-sensitive PDGFR α -activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. *Blood.* 2011 Mar 10;117(10):2935-43. doi: 10.1182/blood-2010-05-286757. Epub 2011 Jan 11. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/21224473>)
- Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, Satoh Y, Shibayama H, Tanaka H, Iwama A, Kanakura Y. FIP1L1-PDGFR α imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. *J Biol Chem.* 2009 Mar 20;284(12):7719-32. doi: 10.1074/jbc.M807489200. Epub 2009 Jan 14. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/19147501>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658066/>)
- Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Muller MC, Beneke H, Muller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Muller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Dohner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A. Recurrent finding of the FIP1L1-PDGFR α fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. *Leukemia.* 2007 Jun;21(6):1183-8. doi: 10.1038/sj.leu.2404662. Epub 2007 Mar 22. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17377585>)
- Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. *Orphanet J Rare Dis.* 2007 Sep 11;2:37. doi: 10.1186/1750-1172-2-37. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17848188>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2045078/>)
- Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. Clinical and molecular features of FIP1L1-PDGFR α (+) chronic eosinophilic leukemias. *Leukemia.* 2004 Apr;18(4):734-42. doi: 10.1038/sj.leu.2403313. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/14973504>)

Last updated September 1, 2015